UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 6-K/A

 

(Amendment No. 1)

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2017

 

Commission File Number: 001-34541

 

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

 

48th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                      Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o                             No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-               .

 

 

 



 

EXPLANATORY NOTE

 

This Amendment No. 1 (the “Amendment”) to the Report of Foreign Private Issuer on Form 6-K (the “Original 6-K”), originally furnished by China Cord Blood Corporation (the “Company”) to the Securities and Exchange Commission on November 20, 2017 containing the financial results for the three and six months ended September 30, 2017 of the Company, amends the Original 6-K to include an unaudited condensed consolidated statement of changes in equity, an unaudited condensed consolidated statements of cash flows, and notes to the unaudited condensed consolidated financial statements and the applicable interactive data file as Exhibit 101, which provides the unaudited condensed consolidated financial statements in XBRL (eXtensible business reporting language), and to provide for the incorporation by reference described below. No other changes have been made to the Original 6-K. This Amendment does not reflect events that may have occurred subsequent to the original submission date and does not modify or update in any way the disclosures made in the Original 6-K.

 

This Amendment and each of the exhibits to this Amendment are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-213730 and No. 333-183143) of the Company.

 

This Amendment contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Amendment is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date this Amendment is filed, and the Company does not intend to update any of the forward-looking statements after the date this Amendment is filed to conform these statements to actual results, unless required by law.

 

The forward-looking statements included in this Amendment are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including the relaxation of China’s one child policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; the proposed transactions between an affiliate of Golden Meditech Holdings Limited (“Golden Meditech”) and Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership); and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

 

2



 

Results of Operations and Financial Condition

 

Following this cover page are the unaudited condensed consolidated financial results for the three months and six months ended September 30, 2017 of the Company.

 

3



 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets

(Amounts expressed in thousands)

 

 

 

 

 

March 31,

 

September 30,

 

 

 

Note

 

2017

 

2017

 

2017

 

 

 

 

 

RMB

 

RMB

 

US$

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

3,510,264

 

3,927,280

 

590,276

 

Accounts receivable, less allowance for doubtful accounts
(March 31, 2017: RMB46,858; September 30, 2017: RMB56,829 (US$8,541))

 

 

 

112,533

 

111,697

 

16,789

 

Inventories

 

 

 

30,987

 

38,756

 

5,825

 

Prepayments and other receivables - Third parties

 

 

 

17,524

 

22,576

 

3,394

 

Prepayments and other receivables - Related parties

 

 

 

 

2,284

 

343

 

Total current assets

 

 

 

3,671,308

 

4,102,593

 

616,627

 

 

 

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

3

 

551,434

 

541,612

 

81,405

 

Non-current deposits - Third parties

 

 

 

237,487

 

236,903

 

35,607

 

Non-current deposits - Related party

 

 

 

 

8,500

 

1,278

 

Non-current accounts receivable, less allowance for doubtful accounts
(March 31, 2017: RMB70,744; September 30, 2017: RMB68,696 (US$10,325))

 

 

 

135,148

 

123,421

 

18,550

 

Inventories

 

 

 

68,775

 

69,843

 

10,497

 

Intangible assets, net

 

 

 

106,686

 

104,376

 

15,688

 

Available-for-sale equity securities

 

 

 

200,790

 

163,038

 

24,505

 

Other investment

 

 

 

189,129

 

189,129

 

28,426

 

Deferred tax assets

 

 

 

22,155

 

25,772

 

3,874

 

Total assets

 

 

 

5,182,912

 

5,565,187

 

836,457

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

Convertible notes, net

 

4

 

1,031,154

 

 

 

Accounts payable

 

 

 

11,060

 

13,125

 

1,973

 

Accrued expenses and other payables

 

 

 

65,162

 

92,238

 

13,864

 

Deferred revenue

 

 

 

323,690

 

374,912

 

56,350

 

Amount due to a related party

 

 

 

4,679

 

10,428

 

1,567

 

Income tax payable

 

 

 

11,383

 

13,294

 

1,998

 

Total current liabilities

 

 

 

1,447,128

 

503,997

 

75,752

 

 

 

 

 

 

 

 

 

 

 

Non-current deferred revenue

 

 

 

1,569,579

 

1,728,471

 

259,792

 

Other non-current liabilities

 

 

 

302,233

 

330,455

 

49,668

 

Deferred tax liabilities

 

 

 

21,423

 

20,985

 

3,154

 

Total liabilities

 

 

 

3,340,363

 

2,583,908

 

388,366

 

 

4



 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets (Continued)

(Amounts expressed in thousands, except share data)

 

 

 

March 31,

 

September 30,

 

 

 

2017

 

2017

 

2017

 

 

 

RMB

 

RMB

 

US$

 

EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ equity of China Cord Blood Corporation

 

 

 

 

 

 

 

Ordinary shares

 

 

 

 

 

 

 

- US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31, 2017 and 113,661,641 shares issued and 113,524,742 shares outstanding as of September 30, 2017

 

50

 

78

 

12

 

Additional paid-in capital

 

936,417

 

1,987,057

 

298,657

 

Treasury stock, at cost
(March 31 and September 30, 2017: 136,899 shares, respectively)

 

(2,815

)

(2,815

)

(423

)

Accumulated other comprehensive income/(loss)

 

24,428

 

(26,166

)

(3,933

)

Retained earnings

 

879,775

 

1,016,505

 

152,783

 

Total equity attributable to China Cord Blood Corporation

 

1,837,855

 

2,974,659

 

447,096

 

 

 

 

 

 

 

 

 

Non-controlling interests

 

4,694

 

6,620

 

995

 

 

 

 

 

 

 

 

 

Total equity

 

1,842,549

 

2,981,279

 

448,091

 

 

 

 

 

 

 

 

 

Total liabilities and equity

 

5,182,912

 

5,565,187

 

836,457

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

5



 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Income

(Amounts expressed in thousands, except per share data)

 

 

 

 

 

Three months ended September 30,

 

Six months ended September 30,

 

 

 

Note

 

2016

 

2017

 

2017

 

2016

 

2017

 

2017

 

 

 

 

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

 

 

184,140

 

234,572

 

35,257

 

357,092

 

458,794

 

68,958

 

Direct costs

 

 

 

(39,088

)

(45,644

)

(6,860

)

(76,521

)

(90,426

)

(13,592

)

Gross profit

 

 

 

145,052

 

188,928

 

28,397

 

280,571

 

368,368

 

55,366

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

 

(2,377

)

(3,664

)

(551

)

(4,326

)

(6,343

)

(953

)

Sales and marketing

 

 

 

(39,642

)

(56,152

)

(8,440

)

(77,834

)

(99,602

)

(14,970

)

General and administrative

 

 

 

(48,289

)

(52,784

)

(7,934

)

(91,532

)

(103,134

)

(15,501

)

Total operating expenses

 

 

 

(90,308

)

(112,600

)

(16,925

)

(173,692

)

(209,079

)

(31,424

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

 

54,744

 

76,328

 

11,472

 

106,879

 

159,289

 

23,942

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (expenses)/income, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

 

4,438

 

5,790

 

870

 

8,715

 

10,617

 

1,596

 

Interest expense

 

 

 

(29,801

)

 

 

(58,634

)

(3,257

)

(490

)

Foreign currency exchange (losses)/gains

 

 

 

(15

)

110

 

17

 

120

 

111

 

17

 

Others

 

 

 

576

 

993

 

149

 

728

 

2,142

 

322

 

Total other (expenses)/income, net

 

 

 

(24,802

)

6,893

 

1,036

 

(49,071

)

9,613

 

1,445

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax

 

 

 

29,942

 

83,221

 

12,508

 

57,808

 

168,902

 

25,387

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

5

 

(12,639

)

(14,525

)

(2,183

)

(24,315

)

(30,246

)

(4,547

)

Net income

 

 

 

17,303

 

68,696

 

10,325

 

33,493

 

138,656

 

20,840

 

Net income attributable to non-controlling interests

 

 

 

(662

)

(1,101

)

(165

)

(1,130

)

(1,926

)

(289

)

Net income attributable to China Cord Blood Corporation’s shareholders

 

 

 

16,641

 

67,595

 

10,160

 

32,363

 

136,730

 

20,551

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to ordinary shares

 

6

 

 

 

 

 

 

 

 

 

 

 

 

 

- Basic

 

 

 

0.22

 

0.60

 

0.09

 

0.44

 

1.22

 

0.18

 

- Diluted

 

 

 

0.22

 

0.60

 

0.09

 

0.44

 

1.22

 

0.18

 

 

6



 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Income (Continued)

(Amounts expressed in thousands)

 

 

 

Three months ended September 30,

 

Six months ended September 30,

 

 

 

2016

 

2017

 

2017

 

2016

 

2017

 

2017

 

 

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive losses, net of nil income taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

- Foreign currency translation adjustments

 

(1,400

)

(8,376

)

(1,259

)

(8,360

)

(20,107

)

(3,022

)

- Unrealized holding losses in available-for-sale equity securities

 

(10,507

)

(18,562

)

(2,790

)

(16,977

)

(30,487

)

(4,582

)

Total other comprehensive losses

 

(11,907

)

(26,938

)

(4,049

)

(25,337

)

(50,594

)

(7,604

)

Comprehensive income

 

5,396

 

41,758

 

6,276

 

8,156

 

88,062

 

13,236

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income attributable to non-controlling interests

 

(662

)

(1,101

)

(165

)

(1,130

)

(1,926

)

(289

)

Comprehensive income attributable to China Cord Blood Corporation’s shareholders

 

4,734

 

40,657

 

6,111

 

7,026

 

86,136

 

12,947

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

7



 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statement of Changes in Equity

(Amounts expressed in thousands, except share data)

 

 

 

China Cord Blood Corporation shareholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

Share capital

 

Additional

 

Treasury stock

 

other

 

 

 

Non-

 

 

 

 

 

No. of

 

 

 

paid-in

 

No. of

 

 

 

comprehensive

 

Retained

 

controlling

 

Total

 

 

 

shares

 

Amount

 

capital

 

shares

 

Amount

 

income/(loss)

 

earnings

 

interests

 

equity

 

 

 

 

 

RMB

 

RMB

 

 

 

RMB

 

RMB

 

RMB

 

RMB

 

RMB

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance as of April 1, 2017

 

73,140,147

 

50

 

936,417

 

(136,899

)

(2,815

)

24,428

 

879,775

 

4,694

 

1,842,549

 

Net income

 

 

 

 

 

 

 

136,730

 

1,926

 

138,656

 

Other comprehensive losses

 

 

 

 

 

 

(50,594

)

 

 

(50,594

)

Share-based compensation

 

 

 

16,508

 

 

 

 

 

 

16,508

 

Issuance of shares upon conversion of convertible notes

 

40,521,494

 

28

 

1,034,132

 

 

 

 

 

 

1,034,160

 

Balance as of September 30, 2017

 

113,661,641

 

78

 

1,987,057

 

(136,899

)

(2,815

)

(26,166

)

1,016,505

 

6,620

 

2,981,279

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance as of September 30, 2017 - US$

 

 

 

$

12

 

$

298,657

 

 

 

$

(423

)

$

(3,933

)

$

152,783

 

$

995

 

$

448,091

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

8



 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Cash Flows

(Amounts expressed in thousands)

 

 

 

Six months ended September 30,

 

 

 

2016

 

2017

 

2017

 

 

 

RMB

 

RMB

 

US$

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Net cash provided by operating activities

 

267,291

 

441,710

 

66,390

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

(18,279

)

(22,045

)

(3,313

)

Proceeds from disposal of property, plant and equipment

 

153

 

28

 

4

 

Acquisition of available-for-sale equity securities

 

(66,154

)

 

 

Net cash used in investing activities

 

(84,280

)

(22,017

)

(3,309

)

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Repayment of bank loan

 

(60,000

)

 

 

Net cash used in financing activities

 

(60,000

)

 

 

 

 

 

 

 

 

 

 

Effect of foreign currency exchange rate change on cash and cash equivalents

 

11,214

 

(2,677

)

(402

)

 

 

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

134,225

 

417,016

 

62,679

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

3,008,422

 

3,510,264

 

527,597

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

3,142,647

 

3,927,280

 

590,276

 

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

Cash paid for income taxes

 

23,504

 

32,390

 

4,868

 

Cash refund for income taxes

 

960

 

 

 

Cash paid for interest, net of capitalized interest

 

52,929

 

1,537

 

231

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

9



 

Notes to the unaudited condensed consolidated financial statements

(Amounts expressed in thousands, except share data)

 

1                                        Principal activities and basis of presentation

 

(a)                                Principal activities

 

China Cord Blood Corporation (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of September 30, 2017, the Group has three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange.

 

The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee.

 

(b)                                Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The condensed consolidated balance sheet as of March 31, 2017 was derived from the audited consolidated financial statements of the Company. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the March 31, 2017 audited consolidated financial statements of the Company included in the Company’s annual report on Form 20-F for the year ended March 31, 2017.

 

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2017, the results of operations for the three months and six months ended September 30, 2016 and 2017, and cash flows for the six months ended September 30, 2016 and 2017 have been made.

 

For the convenience of the readers, certain amounts as of and for the three months and six months ended September 30, 2017 included in the accompanying unaudited condensed consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.6533, being the spot exchange rate of U.S. dollars in effect on September 29, 2017 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on September 30, 2017 or at any other date.

 

10



 

2                                        Summary of significant accounting policies

 

(a)                                Principles of consolidation

 

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company, its majority-owned subsidiaries and a restricted share unit related variable interest entity in which the Company is the primary beneficiary. For consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company, are presented as non-controlling interests. All significant intercompany balances and transactions have been eliminated on consolidation.

 

(b)                                Use of estimates

 

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the estimate of selling price for individual deliverables in multiple-element revenue arrangements, the estimated future number of successful match units over the estimated weighted average remaining useful life of donated cord blood units, the useful lives of property, plant and equipment and intangible assets, the recoverability of property, plant and equipment and intangible assets, the collectibility of accounts receivables, the realizability of inventories and deferred tax assets and the fair values of share-based compensation.

 

3                                        Property, plant and equipment, net

 

Property, plant and equipment, net consist of the following:

 

 

 

March 31,

 

September 30,

 

 

 

2017

 

2017

 

2017

 

 

 

RMB

 

RMB

 

US$

 

 

 

 

 

 

 

 

 

Buildings

 

593,369

 

593,713

 

89,236

 

Leasehold improvements

 

14,864

 

14,864

 

2,234

 

Machineries

 

154,359

 

151,929

 

22,835

 

Motor vehicles

 

17,152

 

18,202

 

2,736

 

Furniture, fixtures and equipment

 

44,266

 

47,504

 

7,140

 

Construction-in-progress

 

2,806

 

3,947

 

593

 

 

 

826,816

 

830,159

 

124,774

 

Less: Accumulated depreciation

 

(275,382

)

(288,547

)

(43,369

)

Total property, plant and equipment, net

 

551,434

 

541,612

 

81,405

 

 

Depreciation expense related to property, plant and equipment for the three months ended September 30, 2016 and 2017 was RMB11,408 and RMB11,199 (US$1,683), respectively. Depreciation expense related to property, plant and equipment for the six months ended September 30, 2016 and 2017 was RMB22,837 and RMB22,796 (US$3,426), respectively.

 

11



 

4                                        Convertible notes

 

On April 27 and October 3, 2012, the Company completed the sale of US$65,000 and US$50,000 in aggregate principal amount of 7% senior unsecured convertible notes to Brilliant China Healthcare Investment Limited (formerly known as KKR China Healthcare Investment Limited) (“BCHIL”) (the “KKR Notes”) and Golden Meditech (the “GM Notes,” and collectively the “Notes”), respectively. The GM Notes were subsequently sold to Cordlife Group Limited and Magnum Opus International Holdings Limited in November 2014. In May 2015, Golden Meditech initiated a series of agreements and transactions to acquire US$115,000 in aggregate principal amount of the Notes. As of January 2016, Golden Meditech, through its wholly owned subsidiary, Golden Meditech Stem Cells (BVI) Company Limited (“GMSC”) became the owner of the Notes.

 

In April 2017, GMSC exercised the conversion of the Notes of US$115,000 at a conversion price of US$2.838 per share, which resulted in the issuance of 40,521,494 ordinary shares of the Company. Subsequent to such conversion, the Company has no outstanding convertible notes.

 

The carrying amounts of the Notes, net are summarized in the following table:

 

 

 

March 31,

 

September 30,

 

 

 

2017

 

2017

 

2017

 

 

 

RMB

 

RMB

 

US$

 

 

 

 

 

 

 

 

 

Principal amount of the KKR Notes

 

449,608

 

 

 

Principal amount of the GM Notes

 

345,852

 

 

 

Cumulative interest payable

 

236,389

 

 

 

Less: Unamortized debt issuance costs

 

(695

)

 

 

Total convertible notes, net

 

1,031,154

 

 

 

 

The Company accrued interest on the Notes based on the guaranteed 12% internal rate of return per annum. The difference between the accrued interest rate of 12% and the coupon rate of 7% of the Notes is recorded in convertible notes in the consolidated balance sheet as of March 31, 2017. Debt issuance costs in connection with the issuance of convertible notes are amortized from the date the Notes were issued to the earliest date the holders of the Notes can demand payment, which is five years. Upon the conversion of the Notes, the carrying value of the Notes (net of the cost of shares issued) were credited to additional paid-in capital.

 

Interest relating to the Notes was recognized as follows:

 

 

 

Three months ended September 30,

 

Six months ended September 30,

 

 

 

2016

 

2017

 

2017

 

2016

 

2017

 

2017

 

 

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

KKR Notes interest incurred

 

16,343

 

 

 

31,905

 

1,454

 

219

 

GM Notes interest incurred

 

11,846

 

 

 

23,320

 

1,113

 

167

 

Amortization of debt issuance costs

 

986

 

 

 

1,941

 

690

 

104

 

Total interest expense

 

29,175

 

 

 

57,166

 

3,257

 

490

 

 

12



 

5                                        Income tax

 

The Company’s PRC subsidiaries are subject to PRC statutory income tax rate of 25% unless otherwise specified.

 

In January 2015, Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) received approval from the tax authority on the renewal of its High and New Technology Enterprises (“HNTE”) status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2014 to December 31, 2016. Beijing Jiachenhong is in the process of reapplication for its HNTE status which will enable it to the preferential income tax rate of 15% from January 1, 2017 to December 31, 2019.

 

In April 2014, Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”) received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2013 to December 31, 2015. In March 2017, Guangzhou Nuoya received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2016 to December 31, 2018.

 

In January 2016, Zhejiang Lukou Biotechnology Co., Ltd. (“Zhejiang Lukou”) received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2015 to December 31, 2017.

 

The Enterprise Income Tax Law and its implementation rules also impose a withholding tax at 10%, unless reduced by a tax treaty or agreement, for dividends receivable by non-PRC-resident enterprises from PRC-resident enterprises in respect of earnings accumulated beginning on January 1, 2008. As of March 31, 2016, the Company has provided aggregated amount of RMB14,300 for withholding income tax on a portion of the undistributed earnings of its PRC subsidiaries according to management’s reinvestment plan. No income taxes were provided for the remaining undistributed earnings which are intended to be reinvested indefinitely in the PRC. During the year ended March 31, 2017, a reversal of withholding income tax of RMB14,300 was made due to the change in management’s future reinvestment plan as all undistributed earnings of the Company’s PRC subsidiaries are intended to be reinvested indefinitely in the PRC in the foreseeable future. As of September 30, 2017, such undistributed earnings that may be subject to the withholding tax amounted to RMB1,797,239 (US$270,128) and the related unrecognized deferred tax liability was RMB179,724 (US$27,013).

 

The Company’s effective income tax rates for the three months ended September 30, 2016 and 2017 were 42.2% and 17.5%, and were 42.1% and 17.9% for the six months ended September 30, 2016 and 2017, respectively. The effective income tax rates for the three months and six months ended September 30, 2016 and 2017 differ from the PRC statutory income tax rate of 25% primarily due to the effect of withholding tax and the effect of non-PRC entities not being subject to income tax, which is offset by the effect of Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou’s preferential tax treatments.

 

As of and for the three months and six months ended September 30, 2017, the Company did not have any material unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

 

13



 

6                                        Earnings per share

 

The following table sets forth the computation of basic and diluted earnings per share for the three months and six months ended September 30, 2016 and 2017 respectively:

 

 

 

 

 

Three months ended September 30,

 

 

 

Note

 

2016

 

2017

 

2017

 

 

 

 

 

RMB

 

RMB

 

US$

 

Numerator:

 

 

 

 

 

 

 

 

 

Net income attributable to the Company’s shareholders

 

 

 

16,641

 

67,595

 

10,160

 

Earnings allocated to participating convertible notes

 

(i)

 

 

 

 

Net income for basic and diluted net income per share

 

 

 

16,641

 

67,595

 

10,160

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

Weighted average ordinary shares outstanding for basic and diluted net income per share

 

 

 

73,003,248

 

113,524,742

 

113,524,742

 

 

 

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

 

 

 

 

 

- Basic

 

 

 

0.22

 

0.60

 

0.09

 

- Diluted

 

(ii)

 

0.22

 

0.60

 

0.09

 

 

 

 

 

 

Six months ended September 30,

 

 

 

Note

 

2016

 

2017

 

2017

 

 

 

 

 

RMB

 

RMB

 

US$

 

Numerator:

 

 

 

 

 

 

 

 

 

Net income attributable to the Company’s shareholders

 

 

 

32,363

 

136,730

 

20,551

 

Earnings allocated to participating convertible notes

 

(i)

 

 

 

 

Net income for basic and diluted net income per share

 

 

 

32,363

 

136,730

 

20,551

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

Weighted average ordinary shares outstanding for basic and diluted net income per share

 

 

 

73,003,248

 

112,196,168

 

112,196,168

 

 

 

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

 

 

 

 

 

- Basic

 

 

 

0.44

 

1.22

 

0.18

 

- Diluted

 

(ii)

 

0.44

 

1.22

 

0.18

 

 


Notes:

 

(i)                         The outstanding convertible notes provide the holders with the ability to participate in any excess cash dividend. Excess cash dividend means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% coupon interest rate in such financial year divided by the number of shares into which the notes are convertible at the conversion price then in effect on the relevant record date. Therefore, net income attributable to the Company’s shareholders is reduced by such allocated earnings to participating convertible notes for each reporting period in both basic and diluted net income per share computation. For the three months ended September 30, 2016 and six months ended September 30, 2016 and 2017, as there was no excess cash dividend, no earnings were allocated to participating convertible notes. There was no such participating right effect for the three months ended September 30, 2017 as all outstanding convertible notes were fully converted in April 2017.

 

(ii)                      During the three months ended September 30, 2016 and six months ended September 30, 2016 and 2017, the Company had potentially dilutive ordinary shares of 40,521,494 representing shares issuable upon conversion of the outstanding convertible notes (Note 4). Such potentially dilutive ordinary shares were excluded from diluted net income per share computation because their effects would have been anti-dilutive.

 

14



 

Other Events

 

On November 20, 2017, the Company issued a press release announcing preliminary unaudited condensed consolidated financial results for the three months and six months ended September 30, 2017. A copy of the press release is attached as Exhibit 99.1.

 

Exhibits

 

Exhibit No.

 

Description

99.1 *

 

Press Release, dated November 20, 2017

101.INS XBRL

 

Instance Document

101.SCH XBRL

 

Taxonomy Extension Schema Document

101.CAL XBRL

 

Taxonomy Extension Calculation Linkbase Document

101.DEF XBRL

 

Taxonomy Extension Definition Linkbase Document

101.LAB XBRL

 

Taxonomy Extension Label Linkbase Document

101.PRE XBRL

 

Taxonomy Extension Presentation Linkbase Document

 


* Previously filed

 

15



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CHINA CORD BLOOD CORPORATION

 

 

 

 

By:

/s/ Albert Chen

 

Name:

Albert Chen

 

Title:

Chief Financial Officer

 

Dated: December 6, 2017

 

16